Aurora Cannabis Reports Record Annual Revenue and EBITDA, Medical Cannabis Sales Up 18%
Summary
Aurora Cannabis announced record annual global medical cannabis net revenue of $288.6 million, an 18% year-over-year increase, alongside record annual adjusted EBITDA of $53.8 million, up 32%. Total net revenue for Q4 2026 rose 10% to $84.8 million. These results underscore the company's successful strategic pivot towards the profitable medical cannabis market, with consumer cannabis revenue declining as planned. The company also noted the completion of the Safari Flower Company acquisition, previously announced in April, which expands its international capacity. With a strong balance sheet of approximately $164.7 million in cash and no debt, this positive financial update is significant for a company trading near its 52-week low.
At the time of this announcement, ACB was trading at $3.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $186.6M. The 52-week trading range was $3.07 to $6.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.